Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cultured Chimeric Skin (CX501) for Epidermolysis Bullosa
NCT00987142Phase 2Completed
- Sponsor
- TiGenix
- Start
- Dec 2006
- Primary completion
- May 2010
- Modality
- Cell Therapies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of CX501 in Recessive Dystrophic Epidermolysis Bullosa (RDEB), sponsored by TiGenix. Started Dec 2006; status: completed.
02
Drugs
CX501
03
Conditions
Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Beyond the preview
Go deeper on NCT00987142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00987142.